SCHEMBL3717751

SCHEMBL3717751

Brc1ccc(NCC2CC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.44
KMT2A Q03164 4/20 0.44
NPC1 O15118 4/20 0.44
PTGER4 P35408 2/20 0.42
AGER Q15109 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
CARM1 Q86X55 1/20 0.39
PRMT6 Q96LA8 1/20 0.39
FPR2 P25090 2/20 0.39
MEN1 O00255 3/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ACHE P22303 1/20 0.38
BACE1 P56817 1/20 0.38
FPR3 P25089 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
PIM1 P11309 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16823551 0.92 RAB9A (0.50) RAB9AKMT2ANPC1PTGER4AGER
SCHEMBL13438637 0.91 PRKCQ (0.42) RAB9AKMT2ANPC1PTGER4AGER
SCHEMBL11934751 0.91 PRKCQ (0.42) RAB9AKMT2ANPC1PTGER4AGER
SCHEMBL20567955 0.90 RAB9A (0.53) RAB9AKMT2ANPC1AGERHDAC3
SCHEMBL23142668 0.82 RAB9A (0.43) RAB9AKMT2ANPC1AGERHDAC3
SCHEMBL23142643 0.82 RAB9A (0.43) RAB9AKMT2ANPC1AGERHDAC3
SCHEMBL15539977 0.80 CARM1 (0.43) RAB9AKMT2ANPC1HDAC3HDAC1
SCHEMBL2935193 0.78 PTGER4 (0.42) RAB9AKMT2ANPC1PTGER4CARM1
SCHEMBL25330831 0.78 JAK2 (0.45) CARM1PRMT6ACHEBACE1ALDH1A1
SCHEMBL3720640 0.78 S1PR1 (0.43) RAB9AKMT2ANPC1AGERCARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568963-A1 TERTIARY AMINE SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS Bristol-Myers Squibb Company (US) 2025-06-18 EP disclosed
CN-119677740-A Tertiary amine substituted bicyclic compounds useful as T cell activators 百时美施贵宝公司 2025-03-21 CN disclosed
WO-2024036101-A1 TERTIARY AMINE SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2024-02-15 WO disclosed
EP-2438049-B1 CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 BOEHRINGER INGELHEIM INT (DE) 2014-05-14 EP disclosed
US-8703765-B2 Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-04-22 US disclosed
US-20120172357-A1 CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-07-05 US disclosed
WO-2010139673-A1 CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172357-A1 CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD11B2, HSD3B1 RAB9A 2934/4885KMT2A 4007/4885NPC1 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.